lutetium (177Lu) vipivotide tetraxetan
Novartis
To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies
The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.
git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/
Example prompts for Pluvicto: